Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes (Q33336433)

25 July 2017

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes (English)

1 reference

25 July 2017

0 references

1 reference

Edwards JC

1

1 reference

PubMed ID

11257159

25 July 2017

Cambridge G

series ordinal

2

1 reference

25 July 2017

1 February 2001

1 reference

25 July 2017

1 reference

25 July 2017

40

1 reference

25 July 2017

205-211

1 reference

25 July 2017

2

1 reference

Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis?

25 July 2017

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.2.205

The structure and origin of rheumatoid factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.2.205

Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.2.205

Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.2.205

Do self-perpetuating B lymphocytes drive human autoimmune disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.2.205

The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.2.205

Differential distribution of Fc gamma RIIIa in normal human tissues and co-localization with DAF and fibrillin-1: implications for immunological microenvironments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.2.205

The ability of synoviocytes to support terminal differentiation of activated B cells may explain plasma cell accumulation in rheumatoid synovium

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.2.205

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.2.205

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.2.205

A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.2.205

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.2.205

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2F40.2.205

10.1093/RHEUMATOLOGY/40.2.205

21 January 2018

Identifiers

DOI

1 reference

25 July 2017

1 reference

PubMed ID

11257159